Pyoderma gangrenosum: signpost of underlying disease.
Pyoderma gangrenosum lesions often arise as small pustules that rapidly expand into large, deep ulcers. Generally, this skin disorder is identified on the basis of its characteristic appearance; there are no tests or pathognomonic histopathologic features that routinely confirm the diagnosis. The go...
| Publicado en: | Consultant (00107069) Vol. 42; no. 4; pp. 457 - 460 |
|---|---|
| Autor principal: | |
| Formato: | Journal Article |
| Publicado: |
HMP Global
2002 Apr 1
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106930203&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 106930203 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00107069 CST jtl: Consultant (00107069) issn: 00107069 maglogo: N pubinfo: dt: 2002 Apr 1 vid: 42 iid: 4 pid: 20465 pub: HMP Global place: Malvern, Pennsylvania artinfo: ui: 106930203 2002061374 106930203 ppf: 457 ppct: 3 formats: tig: atl: Pyoderma gangrenosum: signpost of underlying disease. aug: au: Zuber TJ affil: Associate, Department of Family and Preventive Medicine, Goizueta Business School and Rollins School of Public Health, Emory University, Atlanta sug: subj: Skin Diseases Etiology Ulcer Etiology Necrosis Etiology Chronic Disease Complications ab: Pyoderma gangrenosum lesions often arise as small pustules that rapidly expand into large, deep ulcers. Generally, this skin disorder is identified on the basis of its characteristic appearance; there are no tests or pathognomonic histopathologic features that routinely confirm the diagnosis. The goal of laboratory testing is to exclude other disorders or to identify underlying diseases. Treatment can be difficult; it may take many months for the lesions to resolve. Dressings, compresses, rest, and washing with hydrogen peroxide promote reepithelialization. Topical or intralesional corticosteroids are most helpful for patients with early disease. Systemic corticosteroids are the mainstay of therapy; other options include immunosuppressive and antileprosy drugs. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|